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Multidrug-resistant bacteria cause severe infections in hospitals and communities. Development of new drugs to combat
resistant microorganisms is needed. Natural products of microbial origin are the source of most currently available antibiotics.
We hypothesized that random mutagenesis of Aspergillus oryzae would result in secretion of antibacterial compounds. To
address this hypothesis, we developed a screen to identify individual A. oryzae mutants that inhibit the growth of Methicillinresistant Staphylococcus aureus (MRSA) in vitro. To randomly generate A. oryzae mutant strains, spores were treated with
ethyl methanesulfonate (EMS). Over 3000 EMS-treated A. oryzae cultures were tested in the screen, and one isolate, CAL220,
exhibited altered morphology and antibacterial activity. Culture supernatant from this isolate showed antibacterial activity against
Methicillin-sensitive Staphylococcus aureus, MRSA, and Pseudomonas aeruginosa, but not Klebsiella pneumonia or Proteus vulgaris.
The results of this study support our hypothesis and suggest that the screen used is sufficient and appropriate to detect secreted
antibacterial fungal compounds resulting from mutagenesis of A. oryzae. Because the genome of A. oryzae has been sequenced
and systems are available for genetic transformation of this organism, targeted as well as random mutations may be introduced to
facilitate the discovery of novel antibacterial compounds using this system.

1. Introduction
Antibiotic resistant microorganisms became a medical concern shortly after antibiotics became readily available in
the 1940s. In fact, resistance has typically been identified
within four years of Food and Drug Administration approval
of antibacterial agents [1]. Currently, multidrug-resistant
bacteria such as MRSA, coagulase negative Staphylococci,
and Enterococci cause severe infections in both hospital
and community settings [2]. Development of new drugs to
combat the increasing host of drug resistant microorganisms
is essential if we are to avoid the emergence of pathogens for
which there exist no effective antimicrobial therapies.
Most classes of antibiotics were developed from natural
products produced by fungi or filamentous bacteria. Significantly, the majority of antibiotics still commonly used

today are natural product compounds, or their derivatives,
discovered during the “golden era” of antibiotic discovery
from the 1940s through the 1960s [3]. More recent efforts to
generate new antibiotics based on high-throughput, targetfocused screening of large libraries of synthetic compounds
have largely failed to produce new antibiotics [3, 4]. Generation of novel antibiotic compounds may be possible by
revealing previously untapped chemical diversity in known
natural products. For example, recent studies have shown
that mutations in microbes can activate silent gene clusters,
regulating enzyme activity, and resulting in the production of
uncharacterized compounds, some of which exhibit antimicrobial activity [5].
Aspergillus oryzae is a domesticated filamentous fungus
used in the food fermentation industry. Although A. oryzae
is known to produce antibacterial compounds, such as kojic

2
acid and aspirochlorine, the fungus does not produce significant levels of these compounds under standard food industry
or laboratory culture conditions. Recent work, however,
utilizing manipulation of culture conditions, suggests that
A. oryzae, in common with the closely related Aspergillus
flavus, has the potential to produce a broader range of
secondary metabolites than previously thought possible [6].
Random mutagenesis might facilitate the production of
antibacterial compounds by altering expression of polyketide
synthase or nonribosomal peptide synthetase pathways, the
main pathways involved in fungal secondary metabolism
[7]. Additionally, such mutagenesis could modulate regulation of protein expression and production of antimicrobial
peptides. Filamentous fungi, including Aspergillus giganteus
and Aspergillus clavatus, are known to produce antimicrobial peptides with demonstrated antifungal or antibacterial
activity [8]. It is our hypothesis that random mutagenesis of
A. oryzae may result in strains secreting novel antibacterial
compounds, or increased levels of known antibacterial compounds to detectable levels. To address this hypothesis, a biological screening assay was employed to identify individual A.
oryzae mutants that secrete factors inhibiting the growth of
Methicillin-resistant Staphylococcus aureus (MRSA) in vitro.

2. Materials and Methods
2.1. Bacterial and Fungal Strains. Methicillin-sensitive Staphylococcus aureus (ATCC 25922) and Pseudomonas aeruginosa
(ATCC 27853), as well as Methicillin-resistant Staphylococcus
aureus (MRSA), Klebsiella pneumonia, and Proteus vulgaris
(clinical isolates), were generously provided by Dr. Donald
A. Ferguson, Jr. Ph.D., Director of the Clinical Microbiology Laboratory, Quillen College of Medicine, East Tennessee State University. Aspergillus oryzae (FGSC#A815) was
obtained from the Fungal Genetic Stock Center, University of
Missouri-Kansas City. Bacterial strains were maintained on
blood agar plates at 37∘ C and A. oryzae was maintained on
Sabourad dextrose agar (SAB) plates at 30∘ C until screening
A. oryzae culture supernatants for antibacterial activity (see
below).
2.2. Ethyl Methanesulfonate (EMS) Mutagenesis of Aspergillus
oryzae. A. oryzae spores (Fungal Genetics Stock Center), in
sterile water, were treated with zero (mock), 50, 100, 200, 400,
800, 1600, 3200, or 6400 𝜇g mL−1 EMS overnight at 37∘ C.
Washed and diluted spores were then plated onto SAB plates
and incubated at 37∘ C for 48 hours. The percentage of viable
EMS-treated spores compared to mock treated spores was
determined by counting fungal colonies per plate.
2.3. Screening A. oryzae Culture Supernatants for
Antibacterial Activity
2.3.1. Preparation of A. oryzae Culture Supernatants. A. oryzae nontreated, mock-treated, and 1600 𝜇g mL−1 EMS-treated spores were separately cultured in flat-bottom 96 well
plates in Luria-Bertani (LB) liquid media at a volume of
200 𝜇L per well at an estimated spore density of one or less
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viable spores per well. The plates were incubated at 37∘ C for
four days with no shaking.
2.3.2. Screening Assay of Supernatant Activity against MRSA.
After four days of fungal culture, 100 𝜇L of A. oryzae culture
supernatant was transferred from each well of the 96 well
culture plates to wells in U-bottom 96 well plates containing
100 𝜇L fresh LB media (to provide nutrients that may have
been depleted by fungal growth) and 10 𝜇L of 0.005 OD600
MRSA suspended in sterile phosphate buffered saline (PBS).
Positive control wells for MRSA growth consisted of 200 𝜇L
LB media with no A. oryzae culture supernatant plus the
described MRSA inoculum. Negative control wells consisted
of 200 𝜇L LB media with no bacterial inoculum. The plates
were incubated overnight at 37∘ C with no shaking and
MRSA growth in the presence of 3080 EMS-treated fungal
culture supernatants was visually evaluated. Images were
captured using an Epson Perfection 3200 Photo scanner. The
remaining fungal culture supernatant volumes and associated
mycelia mats were stored at 4∘ C, tightly sealed in the original
96 well fungal culture plates.
2.3.3. Dilution/Isolation of EMS-Treated Putative Antibacterial
A. oryzae. Fungal cultures that yielded supernatant samples
with visible antibacterial activity, as determined by reduced
bacterial growth in the screening assay, were diluted and
isolated. The corresponding fungal mats were retrieved from
4∘ C storage and subcultured onto SAB plates at 37∘ C. When
fungal colony growth was just visible, sterile wooden applicator sticks were used to transfer mycelia growth to gridded
SAB plates and cultures at 37∘ C. Colonies were observed for
morphological differences and retested by repeated fungal
culture and screening assay.
2.4. Characterization of Fungal Colony Size and Onset of Spore
Production. The single isolated antibacterial A. oryzae isolate
and the parental A. oryzae strain were inoculated onto SAB
plates, 300 spores in 10 𝜇L sterile water at the plate center,
and cultured at 37∘ C for two days, then moved to room
temperature for further culture. A Westover Scientific Stereo
Microscope and Sony HQX Digital Still Camera were used
to observe colony size and spore formation at two through
seven days after inoculation. Colony diameter sizes were
quantitated in cm.
2.5. Characterization of Spore Production. The antibacterial
A. oryzae isolate and the parental A. oryzae strain were
inoculated onto SAB plates, 3000 spores in 100 𝜇L sterile
water spread to form lawns of fungal growth, and cultured
at 37∘ C for two days then moved to room temperature
for further culture. At eight days after inoculation, fungal
growth and spore appearance had not visibly changed for
several days for either isolate and spores were harvested
and counted. Briefly, 1.5 cm diameter agar plugs comprising
confluent mycelia growth and visibly densest spore growth
were excised from the parental strain and antibacterial
isolate A. oryzae plates and placed into tightly capped 50 mL
tubes with 10 mL of sterile water. The tubes were shaken
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2.6. Effect of Antibacterial A. oryzae Supernatant on Various
Bacteria. Parental A. oryzae spores and antibacterial A.
oryzae isolate spores were cultured in LB liquid media in
6 well flat-bottom plates at a spore concentration of 5 ×
103 spores mL−1 . The cultures were incubated at 37∘ C for
seven days with no shaking and filtered (0.22 𝜇m). 100 𝜇L
aliquots of the filtered culture supernatants were transferred
to wells in U-bottom 96 well plates containing 100 𝜇L fresh
LB media and 10 𝜇L of a dilute bacterial suspension (0.005
OD600 bacteria suspended in sterile PBS). Positive control
wells for bacterial growth consisted of 200 𝜇L LB media with
no culture supernatant plus the described bacterial inoculum.
Negative control wells consisted of 200 𝜇L LB media with no
bacterial inoculum. The plates were incubated overnight at
37∘ C with no shaking and bacterial growth in the presence
of fungal culture supernatant was visually evaluated. The
following bacteria were evaluated as described: Methicillinsensitive Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, and Proteus vulgaris.
2.7. Liquid Chromatography-Mass Spectroscopy (LC-MS). The
(0.22 𝜇m) filtered parental strain and antibacterial isolate A.
oryzae culture supernatants were analyzed by LC-MS/MS.
Fresh 0.22 𝜇m filtered LB liquid media served as a control.
Chromatography was performed on a Shimadzu liquid chromatography system using a Thermo Aquasil C-18 column
(150 × 4.6 mm, 5 𝜇m particle size) at a flow rate of 0.25 mL
minute−1 . The system was coupled to the Shimadzu ion
trap-time of flight (IT-TOF) mass spectrometer with an
electrospray (ESI) source and consisted of two LC-20AD
pumps with UFLC-XR upgrade, SIL-20ACHT autosampler,
CTO-20A column oven, DGU-20A3 degasser, and CBM-20A
communications module. Data was analyzed with LCMSSolution and Profiler software (Shimadzu). Aliquots of the LB
control and both fungal culture supernatants were eluted
with a mobile phase gradient of 10% acetonitrile, 0.1% formic
acid (90% H2 O) at one minute to 90% acetonitrile, and 0.1%
formic acid (10% H2 O) at 20 minutes.

3. Results and Discussion
In the present study we designed a screening assay to evaluate
antibacterial activity of A. oryzae culture supernatants from
liquid fungal culture. Ethyl Methanesulfonate (EMS) at a
concentration range from 50 to 6400 𝜇g mL−1 was employed
to produce mutations in the A. oryzae genomic DNA. Spore
treatment with EMS concentration of 1600 𝜇g mL−1 resulted
in approximately 25% of control viability (see Figure 1)
and resulted in visibly smaller fungal colony sizes on SAB
agar plates compared to mock treatment or treatment with
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Spore viability (% of control)

vigorously to dislodge the fungal spores into the water (5 ×
30 seconds) and the agar plugs were discarded from the tubes.
Undiluted samples were counted using a hemacytometer and
an Olympus BH-2 microscope at 40x magnification. Three
counts were performed per sample to determine mean spore
concentration, reported as spores mL−1 .
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Figure 1: Ethyl methanesulfonate mutagenesis of Aspergillus oryzae.
Aspergillus oryzae spore viability was reduced in a dose-dependent
manner by ethyl methanesulfonate (EMS) treatment. Spore treatment with 1600 𝜇g mL−1 EMS was used to generate the A. oryzae
mutants screened for secretion of antibacterial compounds.

lower EMS concentrations. Previously, 25% spore viability of
Aspergillus niger was the minimum spore lethality induced
by EMS sufficient to produce detectable auxotrophic mutants
amongst treated spores [9]. Although EMS treatment resulting in higher levels of spore lethality would result in higher
levels of mutation frequency, posttreatment spore viability of
approximately 25% was selected to minimize the number of
mutations per resulting fungal strain. Spore treatment with
EMS concentration of 1600 𝜇g mL−1 was subsequently used
to generate a pool of potential A. oryzae mutants, which were
screened for the secretion of antibacterial compounds.
The screening method used in this study allowed smallvolume (200 𝜇L) liquid culture of putative mutant A. oryzae
spores, visible confirmation of fungal growth in 96 well fungal
culture plates (see Figure 2(a)), and visual examination of Ubottom 96 well plate bacterial cultures subjected to fungal
culture supernatants for reduction in MRSA bacterial growth
(see Figures 2(b) and 2(c)). While manipulation of fungal
culture media and genetic mutation can both be utilized to
alter expression of fungal metabolites [5, 6], mutation reduces
the need for further manipulation of fungal supernatants
containing possible secreted antibacterial compounds prior
to screening for activity. In our study, because the EMStreated spores were cultured in standard bacterial culture
media (LB media), antibacterial activity of fungal culture
supernatants could be assayed directly without extraction of
active compounds and reconstitution in bacteria compatible
media, which would require larger fungal culture volumes.
Mutant fungal strains identified by this method may be
later subjected to culture in various medias or conditions to
determine if such manipulations can contribute to increased
metabolic diversity and/or metabolite yield.
Over 3000 EMS-treated, putative mutant A. oryzae
cultures were tested in the described screening assay for
antibacterial activity. A single EMS-treated A. oryzae isolate, named CAL220, exhibited antibacterial activity in the
screening assay as indicated by complete lack of visible MRSA
growth in the assay. Subculture of assay well contents to LB
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(a)

(b)

(c)

Figure 2: Screening A. oryzae culture supernatants for antibacterial activity. Fungal culture in 96 well plates allows visible confirmation
of fungal growth. As seen in (a), wells with fungal growth are dark, while wells with no fungal growth contain only culture media and are
comparatively clear. Examination of U-bottom 96 well plate bacterial cultures subjected to fungal culture supernatants allows visual evaluation
of reduction in MRSA bacterial growth (b). (c) a magnified area (boxed) of image in (b) clearly showing a single well with extremely reduced
bacterial growth indicating antibacterial activity of fungal culture supernatant.

agar plates showed no bacterial growth and confirmed that
the fungal culture supernatant killed the MRSA bacteria.
Repeated assay of filter sterilized culture supernatant from the
antibacterial A. oryzae isolate showed antibacterial activity
against Staphylococcus aureus (Methicillin-sensitive), MRSA,
and Pseudomonas aeruginosa, but not Klebsiella pneumonia
or Proteus vulgaris.
The compound(s) in the antibacterial A. oryzae culture
supernatant responsible for the observed antibacterial activity have thus far not been isolated, so minimum inhibitory
concentrations cannot be determined at this time. However,
dose-dependent effect of the antibacterial culture supernatant
was evaluated by employing serial dilutions in LB media
of the supernatant in the screening assay. Activity against
Staphylococcus aureus, MRSA, and Pseudomonas aeruginosa
was confirmed in 1 : 2 diluted and 1 : 4 diluted antibacterial
culture supernatant, while further dilutions of the supernatant (1 : 8, 1 : 16, 1 : 32) resulted in lack of complete or
detectable antibacterial activity indicating that the antibacterial compound is present in low concentration in the active
supernatant (data not shown).
Preliminary liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis indicates that the antibacterial fungal culture supernatant contains a single small
molecule species of 𝑚/𝑧 602 with a fragment ion of 𝑚/𝑧 245
not found in the parental fungal culture supernatant or in
the culture media alone (data not shown). While the identity
of this compound has not yet been elucidated, the 𝑚/𝑧
value indicates a possible molecular weight of 601 Da, which
would differentiate it from lower molecular weight compounds such as kojic acid, aspirochlorine, aflatoxin, asperfuran, cyclopiazonic acid, 3-nitropropionic acid, maltoryzine,
sporogen, aflatrem, 13-desoxypaxilline, miyakamides, parasiticolide, and aspergillomarasmine, compounds which have
been previously isolated from A. oryzae and/or the 99.5%

genetically homologous A. flavus [6]. Heat sterilizing the
active supernatant (100∘ C 5–20 minutes) did not diminish
antibacterial activity, while lyophilization and reconstitution
in smaller volumes in an attempt to concentrate the active
compound did reduce activity. This activity reduction is likely
due to increased NaCl2 concentration as increasing NaCl2
concentration to three fold in excess of LB concentration
(10 g L−1 ) in nonlyophilized samples also reduced activity.
The antibacterial A. oryzae isolate exhibited altered morphology consisting of smaller colony size, reduced mycelia
formation, and earlier and heavier visible spore production
(see Figure 3). At all times from one to seven days after inoculation, the parental colony exhibited dense, fluffy mycelia
growth, and little spore production, while the antibacterial
isolate colony exhibited minimal mycelia growth with heavy
spore production. Spore production quantitated from equivalent fungal SAB cultures showed that parental strain A. oryzae
yielded less than 1 × 104 spores mL−1 , while antibacterial
isolate A. oryzae yielded approximately 1.5 × 106 spores mL−1
when using an equal volume of eluent, more than 100 times
as many spores as the parental strain.
Future work in our laboratory will include fractionation and isolation of the antibacterial compound(s) from
the mutant A. oryzae isolate generated in this study. The
results of this study support our hypothesis that random
mutations introduced into the A. oryzae genome can result
in fungal secretion of antibacterial factors and suggest that
the screen used is sufficient and appropriate to detect secreted
antibacterial fungal compounds resulting from mutagenesis.
The genome of A. oryzae has been sequenced, and systems are
available for genetic transformation of this organism. Thus
targeted as well as random mutations may be introduced
to facilitate the discovery of novel antibacterial compounds
using the screening system reported here.
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(a)

(b)

Figure 3: Characterization of mutant Aspergillus oryzae colony size and onset of spore production. The antibacterial A. oryzae isolate (b)
exhibited altered morphology consisting of smaller colony size, reduced mycelia formation, and earlier and heavier visible spore production
compared to parental A. oryzae (a). Colonies are shown at two days after inoculation on SAB plates. Without magnification, spores are visible
as dark coloration (b), while mycelia are bright white (a). Scale bars = 0.75 cm.
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